ReviewCureus2025
Exploring the Interplay Between Hypertension and Osteoporosis: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Novel Approach to Determining Bone Loss Through Serum Uric Acid Levels: A Retrospective Multicenter Cohort Analysis.Journal of clinical medicine · 2026Article
- Poor Bone Health Associated with Reduced Cerebral Perfusion and Brain Volume in Older Adults.Diagnostics (Basel, Switzerland) · 2026Article
- Effect of amlodipine and telmisartan on bone metabolism markers in newly diagnosed hypertensive patients.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension and osteoporosis are highly prevalent chronic conditions that have significant implications for global health, especially in aging populations. While these conditions have traditionally been viewed as separate, emerging research suggests a strong pathophysiological link between the two. Understanding these shared mechanisms may help improve screening and guide integrated management strategies. This narrative review was conducted between January 2024 and July 2025 using PubMed, ScienceDirect, and Google Scholar. The search strategy used the Boolean string: ("hypertension" OR "high blood pressure") AND ("osteoporosis" OR "bone loss"), supplemented with pharmacologic terms ("ACE inhibitors," "angiotensin receptor blockers," "thiazide diuretics," "beta-blockers", "SERMS", "Bisphosphonates", "Denosumab", "romosozumab", and "teriparatide"). Filters included English language, peer-reviewed human and animal studies when mechanically relevant. A total of 336 articles were retrieved, 143 titles and abstracts were screened, and 61 articles were selected. Data were synthesized qualitatively and organized thematically. Evidence demonstrates that oxidative stress and the renin-angiotensin-aldosterone system (RAAS) activation serve as strong mechanisms linking osteoporosis and hypertension. These pathways promote endothelial dysfunction, osteoclastogenesis, and impaired osteoblast activity. Hormonal disturbances such as estrogen deficiency can further exacerbate both vascular and skeletal deterioration. Several antihypertensive medications, including thiazide diuretics, angiotensin-converting enzyme inhibitors (ACEis), and angiotensin II receptor blockers (ARBs), show bone protective effects; however, most osteoporosis medications exhibit neutral or mixed influence on the cardiovascular system. Hypertension and osteoporosis share connected biological pathways that contribute to both vascular dysfunction and bone loss. Recognizing this connection can encourage therapeutic approaches and address cardiovascular and skeletal health. Further research is needed to define appropriate dual interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.